Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.68, No.3, p.528–534,2021 |
||
| Title: Aberrant promoter methylation of T-cadherin in sera is associated with a poor prognosis in oral squamous cell carcinoma | ||
| Author: Qiuju Wang, Yan Chen, Yibo Chen, Jian Jiang, Xiaoyu Song, Li Zhang, Qiao He, Bo Ye, Lichun Wu, Rui Wu, Qin Lai, Dongsheng Wang, Yanzhen Zhao | ||
| Abstract: T-cadherin functions as a suppressor gene, which is frequently inactivated by aberrant promoter methylation in several human cancers, but its methylation status in oral squamous cell carcinoma (OSCC) has been scarcely studied. Thus this study aimed at exploring the clinical significance and prognostic value of T-cadherin methylation in sera of patients with OSCC. Methylation-specific PCR (MSP) and bisulfate sequencing PCR (BSP) was performed to examine the methylation status of T-cadherin. Then, the associations between methylation status of T-cadherin and various clinicopathological variables or patient survival were investigated in 202 patients with OSCC and 68 controls. T-cadherin methylation was detected in 62 out of 202 (30.7%) patients with OSCC, and the methylation status of T-cadherin in corresponding tissues was confirmed by BSP. Methylation of T-cadherin was significantly associated with advanced tumor T-stage (P ecurrence (P = 0.001). In addition, patients with methylation of T-cadherin had worse overall survival (P = 0.018) and progression-free survival (P CI: 1.112-9.624, P = 0.007) and progression-free survival (HR: 4.201, 95% CI: 1.562-10.038, P equently detected in sera of patients with OSCC, which was associated with risk factors of poor outcomes, and may act as a potential independent prognostic marker for patients with OSCC. |
||
| Keywords: T-cadherin; methylation; serum; prognosis; OSCC | ||
| Published online: 10-Feb-2021 | ||
| Year: 2021, Volume: 68, Issue: 3 | Page From: 528, Page To: 534 | |
| doi:10.4149/neo_2021_201110N1203 |
||
|
|
 download file |
|